Ongericimab Injection (JUNSHID®) Approved For Use In China

On October 11, 2024, Junshi Biosciences announced that its self-developed recombinant humanized anti-PCSK9 monoclonal antibody injection, Ongericimab (brand name: JUNSHID®).

Has been approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed hyperlipidemia.

Ongericimab Injection Clinical Research Findings

Ongericimab Injection has demonstrated significant lipid-lowering effects in several key clinical studies.

In the JS002-003 study, patients receiving Ongericimab treatment for 12 weeks experienced a substantial reduction in low-density lipoprotein cholesterol (LDL-C) levels, exceeding 70%.

Additionally, the JS002-006 study showed that Ongericimab could significantly lower LDL-C levels by over 60% and reduce lipoprotein(a) [Lp(a)] levels by more than 50%, achieving the most substantial reductions among all PCSK9 inhibitors.

Ongericimab Injection Product Specifications and Indications

Ongericimab Injection drug is available in a 150mg (1ml) per vial formulation, offered in both prefilled syringes and prefilled autoinjectors. Its primary indications include:

• In combination with statins or with statins and ezetimibe, for adult patients with primary hypercholesterolemia (non-familial) and mixed hyperlipidemia who are unable to achieve LDL-C targets with diet control alone.

Ongericimab Injection Market Outlook

Cardiovascular diseases, particularly atherosclerotic cardiovascular diseases (ASCVD), have become the leading cause of death among urban and rural residents in China. Elevated LDL-C levels are a significant pathogenic factor in ASCVD.

The approval of Ongericimab provides a new treatment option for patients who cannot achieve lipid control targets with existing therapies, offering the potential to significantly improve lipid control rates and reduce the incidence of cardiovascular events, thereby enhancing long-term patient outcomes.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies.

The company has established a diverse product pipeline encompassing over 50 innovative drugs across five major therapeutic areas: oncology, autoimmune diseases, chronic metabolic diseases, neurological disorders, and infectious diseases.

To date, four products have been approved for marketing in China, the United States, and Europe, including the PD-1 inhibitor Toripalimab (TUOYI), the first self-developed drug approved in these regions.

The approval of Ongericimab Injection marks a significant advancement in the treatment of cardiovascular diseases in China, providing patients with a more effective therapeutic option.

However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.

We welcome you to reach out to us to get Ongericimab Injection price. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.

Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.

Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.